Positron emission tomography scanning: Current and future applications

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 89-112

  Czernin, Johannes ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical applications; FDG; Oncology; Whole body PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER STAGING; CELL METABOLISM; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NODULE; LYMPHOMA; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ENERGY METABOLISM; FLUORODEOXYGLUCOSE F18; FORECASTING; HUMANS; NEOPLASM STAGING; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; UNITED STATES;

EID: 0036176751     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104028     Document Type: Review

References (119)

1. The metabolism of cancer cells
2. Studies upon a tranplantable rat tumour
3. Enzymology of cancer cells (Part 1)
4. Enzymology of cancer cells (Part 2)
5. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and sarc oncogenes
6. Application of annihilation coincidence detection to transaxial reconstruction tomography
7. Cost-effectiveness of PET imaging in clinical oncology
8. Evaluating tumor biology and oncological disease with positron emission tomography
9. PET and 18-F-FDG in oncology: A clinical update
10. Positron emission tomography using 18F-fluorodeoxyglucose in oncology
11. Positron emission tomography provides molecular imaging of biological processes
12. A tabulated summary of the FDG-PET literature
13. CT of the solitary pulmonary nodule
14. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
15. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules; potential role in evaluation and management
16. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning
17. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography
18. Probability of malignancy in solitary pulmonary nodule using fluorine-18-FDG and PET
19. Evaluation of pulmonary lesions with FDG-PET: Comparison of findings in patients with and without a history of prior malignancy
20. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
21. Pulmonary nodules: Differential diagnosis using 18F-fluorodeoxyglucose single photon emission tomography
22. Pulmonary abnormalities and PET data analysis: A retrospective study
23. Prospective investigation of positron emission tomography in lung nodules
24. Likelihood of malignancy in a solitary pulmonary nodule: Comparison of Bayesian analysis and results of FDG-PET scan
25. Analytical decision model for the cost-effective management of solitary pulmonary nodules
26. Value of the new TNM staging system for lung cancer
27. Roentgenographic evaluation of mediastinal lymph nodes for pre-operative assessment in lung cancer
28. Bronchogenic carcinoma: Incidence of metastases to normal sized lymph nodes
29. CT and MRI imaging in staging non-small cell bronchogenic carcinoma: Report of the radiologic diagnostic oncology group
30. Value of computed tomography and mediastinoscopy in pre-operative evaluation of mediastinal nodes in non-small cell lung cancer
31. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography
32. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose
33. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis
34. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma
35. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
36. Non-small cell lung cancer: Nodal staging with FDG-PET versus correlative lymph node mapping and sampling
37. Staging non-small cell lung cancer with whole body PET
38. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
39. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT
40. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: Preliminary prospective evaluation
41. Mediastinal staging of non-small-cell lung cancer with positron emission tomography
42. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients
43. A combined PET/CT scanner for clinical oncology
44. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps
45. Staging non-small cell lung cancer by whole body positron emission tomographic imaging
46. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer
47. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
48. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
49. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
50. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of nonsmall-cell lung carcinoma
51. Prospective survey of referring physicians to determine the impact of whole body FDG-PET on management of cancer patients. 2000
52. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
53. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis
54. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis
55. Positron emission tomography for preoperative staging of colorectal carcinoma
56. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
57. 111In anti-CEA monoclonal antibody
58. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
59. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer
60. Whole-body PET imaging with [18F]Fluorodeoxyglucose in management of recurrent colorectal cancer
61. Staging recurrent metastatic colorectal carcinoma with PET
62. 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective
63. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
64. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma
65. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
66. Detection of lymphoma in bone marrow by whole-body positron emission tomography
67. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
68. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
69. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose
70. Whole body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
71. Whole body positron emission tomography for diagnosis of residual mass in patients with lymphoma
72. The role of positron emission tomography (PET) in the management of lymphoma patients
73. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma
74. A review of the literature for whole-body FDG PET in the management of patients with melanoma
75. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
76. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma
77. Impact of FDG-PET on management of patients with melanoma
78. Imaging of breast cancer with [F18]fluorodeoxyglucose and positron emission tomography
79. Primary and metastatic breast carcinoma: Initial clinical evaluation with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
80. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
81. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
82. Evaluation of breast masses and axillary lymph nodes with [F-18] 2 deoxy-2-fluoro-D-glucose PET
83. Evaluation of pre-operative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
84. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
85. Diagnostic value of positron emission tomography for detecting breast cancer
86. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
87. Positron emission tomography in breast cancer: A clinicopathological correlation of results
88. Results of preliminary clinical trials of the positron emission mammography system PEM-1: A dedicated breast imaging system producing glucose metabolic images using FDG
89. Prospective evaluation of fluorine-18-FDG PET in pre-surgical staging of the axilla in breast cancer
90. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the pre-operative detection of axillary metastases of breast cancer: The experience of the national cancer institute of Milan
91. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures
92. Axillary lymph node metastases: Screening with [Fl8] 2-deoxy-2-D-glucose (FDG) PET
93. Qualitative [18F] FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
94. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
95. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
96. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
97. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to anti-estrogen therapy
98. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
99. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
100. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose
101. Primary and recurrent early stage laryngeal cancer: Preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging
102. Clinical utility of FDG-PET in detecting head and neck tumors: A comparison of diagnostic methods and modalities
103. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose
104. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation
105. Use of positron emission tomography with fluorodeoxyglucosein patients with extracranial head and neck cancers
106. Prospective comparison of 18FFDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
107. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer
108. Evaluation of chemotherapeutic response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography
109. Surveillance for recurrent head and neck cancer using positron emission tomography
110. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas
111. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer
112. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
113. Carbon-11-thymidine and FDG to measure therapy response
114. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo
115. Imaging of adenoviral-directed herpes implex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir
116. PET imaging of transgene expression
117. Imaging transgene expression with radionuclide imaging technologies
118. Performance evaluation of microPET: A high resolution lutetium oxyorthosilicate PET scanner for animal imaging